• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

    11/8/24 4:33:36 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care
    Get the next $CLPT alert in real time by email
    SC 13G/A 1 sc13ga410022clpt_11082024.htm

     UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No. 4)1

     

    ClearPoint Neuro, Inc.

     (Name of Issuer)

    Common Stock, par value $0.01 per share

     (Title of Class of Securities)

    55347P209

     (CUSIP Number)

    September 30, 2024

     (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       ☐  Rule 13d-1(b)

       ☒  Rule 13d-1(c)

       ☐  Rule 13d-1(d)

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 55347P209

     

      1   NAME OF REPORTING PERSON  
             
            Bigger Capital Fund, LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         1,106,827 shares of Common Stock  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              1,106,827 shares of Common Stock  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,106,827 shares of Common Stock  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            4.0%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    2

    CUSIP No. 55347P209

      1   NAME OF REPORTING PERSON  
             
            Bigger Capital Fund GP, LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         1,106,827 shares of Common Stock  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              1,106,827 shares of Common Stock  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            1,106,827 shares of Common Stock  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            4.0%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    3

    CUSIP No. 55347P209

     

      1   NAME OF REPORTING PERSON  
             
            District 2 Capital Fund LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         418,402 shares of Common Stock  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              418,402 shares of Common Stock  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            418,402 shares of Common Stock  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            1.5%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    4

    CUSIP No. 55347P209

     

      1   NAME OF REPORTING PERSON  
             
            District 2 Capital LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         418,402 shares of Common Stock  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              418,402 shares of Common Stock  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            418,402 shares of Common Stock  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            1.5%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    5

    CUSIP No. 55347P209

     

      1   NAME OF REPORTING PERSON  
             
            District 2 GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         418,402 shares of Common Stock  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              418,402 shares of Common Stock  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            418,402 shares of Common Stock  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            1.5%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    6

    CUSIP No. 55347P209

     

      1   NAME OF REPORTING PERSON  
             
            District 2 Holdings LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         418,402 shares of Common Stock  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              418,402 shares of Common Stock  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            418,402 shares of Common Stock  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            1.5%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    7

    CUSIP No. 55347P209

     

      1   NAME OF REPORTING PERSON  
             
            Michael Bigger  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            USA  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         40,692 shares of Common Stock  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         2,005,229 shares of Common Stock*  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              40,692 shares of Common Stock  
        8   SHARED DISPOSITIVE POWER  
               
              2,005,229 shares of Common Stock*  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            2,045,921 shares of Common Stock*  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            7.4%*  
      12   TYPE OF REPORTING PERSON  
             
            IN  

      

    * Consists of 1,106,827 shares of Common Stock owned by Bigger Capital, 418,402 shares of Common Stock owned by District 2 CF, 162,000 shares of Common Stock held by Patricia Winter, the spouse of Mr. Bigger and an aggregate of 318,000 shares of Common Stock held by the sons of Mr. Bigger.

    8

    CUSIP No. 55347P209

     

      1   NAME OF REPORTING PERSON  
             
            Patricia Winter  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Austria  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         162,000 shares*  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         0  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              162,000 shares*  
        8   SHARED DISPOSITIVE POWER  
               
              0  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            162,000*  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than one percent  
      12   TYPE OF REPORTING PERSON  
             
            IN  

      

    * Excludes shares deemed beneficially owned by Michael Bigger, the spouse of Ms. Winter.

    9

    CUSIP No. 55347P209

     

    Item 1(a).Name of Issuer:

    ClearPoint Neuro, Inc., a Delaware corporation (the “Issuer”).

    Item 1(b).Address of Issuer’s Principal Executive Offices:

    120 S. Sierra Avenue
    Suite 100
    Solana Beach, CA 92075

     

    Item 2(a).Name of Person Filing
    Item 2(b).Address of Principal Business Office or, if None, Residence
    Item 2(c).Citizenship

    Bigger Capital Fund, LP (“Bigger Capital”)

    2250 Red Springs Drive

    Las Vegas, NV 89135

    Citizenship: Delaware

     

    Bigger Capital Fund GP, LLC (“Bigger GP”)

    2250 Red Springs Drive

    Las Vegas, NV 89135

    Citizenship: Delaware

     

    District 2 Capital Fund LP (“District 2 CF”)

    175 W. Carver Street

    Huntington, NY 11743

    Citizenship: Delaware

     

    District 2 Capital LP (“District 2”)

    175 W. Carver Street

    Huntington, NY 11743

    Citizenship: Delaware

     

    District 2 GP LLC (“District 2 GP”)

    175 W. Carver Street

    Huntington, NY 11743

    Citizenship: Delaware

     

    District 2 Holdings LLC (“District 2 Holdings”)

    175 W. Carver Street

    Huntington, NY 11743

    Citizenship: Delaware

     

    Michael Bigger

    2250 Red Springs Drive

    Las Vegas, NV 89135

    Citizenship: USA

     

    Patricia Winter

    2250 Red Springs Drive

    Las Vegas, NV 89135

    Citizenship: Austria

     

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

    10

    CUSIP No. 55347P209

    Item 2(d).Title of Class of Securities:

    Common Stock, $0.01 par value (the “Common Stock”).

    Item 2(e).CUSIP Number:

    55347P209

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
        /x/ Not applicable.
           
      (a) / / Broker or dealer registered under Section 15 of the Exchange Act.
           
      (b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
           
      (c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
           
      (d) / / Investment company registered under Section 8 of the Investment Company Act.
           
      (e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
      (f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
      (g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
      (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
      (i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
           
      (j) / / A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J).  
           
      (k) / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
           
          If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4.Ownership
    (a)Amount beneficially owned:

    As of November 7, 2024, Bigger Capital beneficially owned 1,106,827 shares of Common Stock.

    11

    CUSIP No. 55347P209

    Bigger GP, as the general partner of Bigger Capital, may be deemed to beneficially own the 1,106,827 shares of Common Stock beneficially owned by Bigger Capital.

    As of November 7, 2024, District 2 CF beneficially owned 418,402 shares of Common Stock.

    District 2, as the investment manager of District 2 CF, may be deemed to beneficially own the 418,402 shares of Common Stock beneficially owned by District 2 CF.

    District 2 GP, as the general partner of District 2 CF, may be deemed to beneficially own the 418,402 shares of Common Stock beneficially owned by District 2 CF.

    District 2 Holdings, as the managing member of District 2 GP, may be deemed to beneficially own the 418,402 shares of Common Stock beneficially owned by District 2 CF.

    Mr. Bigger, as the managing member of Bigger GP and the managing member of District 2 Holdings, may be deemed to beneficially own the (i) 1,106,827 shares of Common Stock beneficially owned by Bigger Capital and (ii) 418,402 shares of Common Stock beneficially owned by District 2 CF. Mr. Bigger also may be deemed the beneficial owner of 162,000 shares of Common Stock owned by his spouse Patricia Winter and an aggregate of 318,000 shares of Common Stock held by the sons of Mr. Bigger. In addition, Mr. Bigger owns 40,692 shares of Common Stock in his IRA account.

    Ms. Winter holds 162,000 shares.

    The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares of Common Stock owned by another Reporting Person. Each of Bigger GP and Mr. Bigger disclaims beneficial ownership of the shares of Common Stock beneficially owned by Bigger Capital. Each of District 2, District 2 GP, District 2 Holdings and Mr. Bigger disclaims beneficial ownership of the shares of Common Stock beneficially owned by District 2 CF, Mr. Bigger disclaims beneficial ownership of the shares held by Patricia Winter and by the sons of Mr. Bigger, and Ms. Winter disclaims beneficial ownership of the shares of Common Stock held by Mr. Bigger. The filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

    (b)Percent of class:

    The following percentages are based on 27,584,699 shares of Common Stock outstanding as of October 31, 2024, as represented in the Company’s Form 10-Q for the period ended September 30, 2024.

    As of the close of business on November 7, 2024, (i) each of Bigger Capital and Bigger GP may be deemed to beneficially own approximately 4.0% of the outstanding shares of Common Stock, (ii) each of District 2 CF, District 2, District 2 GP and District 2 Holdings may be deemed to beneficially own 1.5% of the outstanding shares of Common Stock, (iii) Mr. Bigger may be deemed to beneficially own approximately 7.4% of the outstanding shares of Common Stock, and (iv) Ms. Winter may be deemed to beneficially own less than one percent of the outstanding Common Stock.

    12

    CUSIP No. 55347P209

    (c)Number of shares as to which such person has:
    (i)Sole power to vote or to direct the vote

    See Cover Pages Items 5-9.

    (ii)Shared power to vote or to direct the vote

    See Cover Pages Items 5-9.

    (iii)Sole power to dispose or to direct the disposition of

    See Cover Pages Items 5-9.

    (iv)Shared power to dispose or to direct the disposition of

    See Cover Pages Items 5-9.

    Item 5.Ownership of Five Percent or Less of a Class.

    Not Applicable.

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    Bigger GP and Mr. Bigger may be deemed to share voting and dispositive power over the shares of Common Stock beneficially owned by Bigger Capital. District 2, District 2 GP, District 2 Holdings and Mr. Bigger may be deemed to share voting and dispositive power over the shares of Common Stock beneficially owned by District 2 CF. Mr. Bigger may be deemed to share voting and dispositive power over the shares of Common Stock held by Ms. Winter and the sons of Mr. Bigger.

    Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not Applicable.

    Item 8.Identification and Classification of Members of the Group.

    See Exhibit 99.1. Previously Filed.

    Item 9.Notice of Dissolution of Group.

    Not Applicable.

    Item 10.Certifications.

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    13

    CUSIP No. 55347P209

    SIGNATURE

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: November 8, 2024

    Bigger Capital Fund, LP   Bigger Capital Fund GP, LLC
         
    By: Bigger Capital Fund GP, LLC, its general partner   By:

    /s/ Michael Bigger

            Michael Bigger
    By:

    /s/ Michael Bigger

        Managing Member
      Michael Bigger      
      Managing Member      
          District 2 Capital LP
             
    District 2 Capital Fund LP   By:

    /s/ Michael Bigger

            Michael Bigger
    By: District 2 GP LLC, its general partner     Managing Member
             
    By:

    /s/ Michael Bigger

         
      Michael Bigger   District 2 Holdings LLC
      Managing Member      
          By:

    /s/ Michael Bigger

            Michael Bigger
    District 2 GP LLC     Managing Member
             
    By:

    /s/ Michael Bigger

         
      Michael Bigger  

    /s/ Michael Bigger

      Managing Member   Michael Bigger
           
           
         

    /s/ Patricia Winter

          PATRICIA WINTER
           
           

     

     

    14

    Get the next $CLPT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLPT

    DatePrice TargetRatingAnalyst
    7/25/2024$10.00Buy
    B. Riley Securities
    10/24/2023$8.00Buy
    Stifel
    2/16/2023$14.00Buy
    B. Riley Securities
    4/5/2022$15.00Buy
    B. Riley Securities
    More analyst ratings

    $CLPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fletcher R John was granted 486 shares, increasing direct ownership by 0.52% to 94,398 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      4/2/25 8:23:54 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Director Richards Timothy T. was granted 938 shares, increasing direct ownership by 1% to 66,288 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      4/2/25 8:22:36 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Director Girin Pascal E R was granted 525 shares, increasing direct ownership by 0.70% to 75,018 units (SEC Form 4)

      4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

      4/2/25 8:21:29 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    $CLPT
    Leadership Updates

    Live Leadership Updates

    See more
    • ClearPoint Neuro Announces Appointment of Mazin Sabra as Chief Operating Officer

      SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mazin Sabra will join the Company effective October 10th as Chief Operating Officer. Mr. Sabra will report directly to Joe Burnett, ClearPoint Neuro's Chief Executive Officer, and serve as a member of the Company's senior leadership team. "We are thrilled to have Mazin join our team and bring his valuable and relevant skill set into our organization," commented Joe Burnett, President and CEO at ClearPoint Neuro. "Our pharma and device partners in many ways view ClearP

      9/20/22 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro, Inc. Announces Appointment of Mary McNamara-Cullinane as Vice President of Regulatory Affairs

      SOLANA BEACH, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mary McNamara-Cullinane has joined the Company as Vice President of Regulatory Affairs. Ms. McNamara-Cullinane will report directly to Joe Burnett, ClearPoint Neuro's Chief Executive Officer, and serve as a member of the Company's senior leadership team. "We are thrilled to welcome Mary to our team as we fully expect her leadership and experience in Regulatory Affairs will contribute immediately to our partners and to patients globally," commented Joe Burnett, Presiden

      8/8/22 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro, Inc. Announces Appointment of Lynnette C. Fallon to Board of Directors

      SOLANA BEACH, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, is pleased to announce that Lynnette C. Fallon has been appointed to the Company's Board of Directors effective immediately. Ms. Fallon will also become a member of the Company's Audit Committee. Ms. Fallon is the Executive Vice President, HR/Legal, General Counsel and Secretary of Axcelis Technologies, Inc. (NASDAQ:ACLS), a provider of equipment and service solutions for the semiconductor manufacturing industry, with locations in eight countries. Ms. Fallon has held her current position sin

      7/15/21 4:30:00 PM ET
      $CLPT
      $ACLS
      Medical/Dental Instruments
      Health Care
      Industrial Machinery/Components
      Technology

    $CLPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

      SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

      11/12/24 2:35:26 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

      SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

      11/8/24 4:33:36 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

      SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

      11/4/24 11:28:38 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    $CLPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities resumed coverage on ClearPoint Neuro with a new price target

      B. Riley Securities resumed coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $10.00

      7/25/24 8:27:37 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • Stifel initiated coverage on ClearPoint Neuro with a new price target

      Stifel initiated coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $8.00

      10/24/23 6:18:03 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • B. Riley Securities resumed coverage on ClearPoint Neuro with a new price target

      B. Riley Securities resumed coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $14.00

      2/16/23 7:44:43 AM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    $CLPT
    Financials

    Live finance-specific insights

    See more
    • ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024

      SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 third quarter on Thursday, November 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 third quarter on Thursday, November 7th at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 428-7458, or a

      10/17/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024

      SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 second quarter on Wednesday, August 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 second quarter on Wednesday, August 7th at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 428-7458, or

      7/17/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024

      SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 first quarter on Tuesday, May 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 first quarter on Tuesday, May 7th, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (201

      4/23/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care

    $CLPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $CLPT
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CLPT
    SEC Filings

    See more
    • November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

      For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

      11/14/24 8:50:18 AM ET
      $CLPT
      $PTCT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain

      Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United StatesSOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the U.S. Food and Drug Administration (FDA) has granted marketing authorization for the SmartFlow Neuro Cannula using the De Novo pathway. The SmartFlow Neuro Cannula is intended for intraputaminal administration of PTC Therapeutics' gene therapy KEBILIDI™ (eladocagene exuparvovec-tneq) for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. This signifies th

      11/13/24 1:20:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro Reports Third Quarter 2024 Results

      Achieved Record Revenue and Growth of 41%; Operational Cash Burn Reduced to $1.2 Million SOLANA BEACH, CA / ACCESSWIRE / November 7, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2024.Third Quarter HighlightsReported quarterly revenue of $8.1 million, a 41% year-over-year increase;Accelerated growth of SmartFrame OR™ platform and ClearPoint Prism® Laser Therapy System, contributing to record navigation and device revenue of $2.9 million, a 53% year-over-year increase;Overall product revenue, inc

      11/7/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024

      President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast TodaySOLANA BEACH, CA / ACCESSWIRE / October 31, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced participation in multiple investor conferences and interview formats including Bloomberg Intelligence Vanguards of Healthcare Podcast series published today. The link to the interview published this morning on Bloomberg can be found HERE.Healthcare Conferences with Participation of ClearPoint Neuro Management Include:UBS Global Healthcare Conference in

      10/31/24 4:05:00 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by ClearPoint Neuro Inc.

      DEF 14A - ClearPoint Neuro, Inc. (0001285550) (Filer)

      4/9/25 4:22:15 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-K filed by ClearPoint Neuro Inc.

      10-K - ClearPoint Neuro, Inc. (0001285550) (Filer)

      2/26/25 5:17:38 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care
    • ClearPoint Neuro Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ClearPoint Neuro, Inc. (0001285550) (Filer)

      2/26/25 4:05:29 PM ET
      $CLPT
      Medical/Dental Instruments
      Health Care